No information is available on the clinical use of fruquintinib during breastfeeding. Because fruquintinib is 95% bound to plasma proteins, the amount in milk is likely to be low. However, the manufacturer recommends that breastfeeding be discontinued during fruquintinib therapy and for 2 weeks after the last dose.